Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)

NCT01637090 is registered in ClinicalTrials.gov with Adam Lerner as lead sponsor.

NCT NCT01637090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01637090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)
Lead sponsor
Adam Lerner
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2012
Completion date
May 31, 2015
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma